Background: Although the control of varicella outbreaks is an important health issue, cost could present a major barrier for vaccination. The aim of this study is to investigate the association of vaccine subsidies and caregivers' socioeconomic status with varicella vaccine coverage of their children in Greater Tokyo, Japan, before the period that varicella vaccination was included in routine immunization program.
Methods: Participants were recruited from two different cities. In Chiba city, parents of 18-month-old infants (N = 378) undergoing a medical examination in July 2013 were recruited at a clinic where no subsidy for varicella immunization was provided. In Nishitokyo city, parents of 24- to 30-month-old children (N = 315) undergoing a health checkup in July and August 2013 were recruited at a clinic where a partial subsidy was provided. The association between household income and varicella immunization was investigated by multivariate logistic regression stratified by city.
Results: Vaccine coverage was 61.0% in Chiba city and 73.3% in Nishitokyo city. In Chiba city, odds ratios of middle and high household income for varicella immunization were 4.22 [95% confidence interval (CI): 1.65-10.7] and 5.94 (95% CI: 1.89-18.6), respectively, compared to low household income. However, household income was not associated with varicella vaccination in Nishitokyo city. Neither working status nor education was associated with vaccination in both cities.
Conclusion: While household income was associated with high vaccine coverage in the city with no vaccine subsidy, this association was not observed in the city where the subsidy was given, which suggests that cost is a barrier for varicella immunization. Thus, in countries where varicella vaccination is not included in routine immunization programs, introducing subsidies nationwide or routine immunization programs for varicella vaccination would be an important approach to eliminate inequality in vaccine coverage.
Download full-text PDF |
Source |
---|---|
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4791386 | PMC |
http://dx.doi.org/10.3389/fped.2016.00019 | DOI Listing |
Case Rep Gastrointest Med
January 2025
Department of Gastroenterology and Hepatology, Michigan Medicine, Ann Arbor, Michigan, USA.
Novel therapeutics used in the treatment of inflammatory bowel disease pose an increased risk of viral reactivation in patients. We present a case of a patient with refractory Crohn's disease (CD) who developed primary varicella (chickenpox) of a vaccine-viral strain after receiving combination immunosuppression with high-dose corticosteroids, tumor necrosis factor inhibitor (TNFi), and a Janus kinase inhibitor (JAKi) in the hospital. While this patient recovered and did not experience long term adverse effects, her case provides an opportunity for improvement.
View Article and Find Full Text PDFPLOS Glob Public Health
January 2025
MSD LATAM, San José, Costa Rica.
Varicella presents a public health challenge in Guatemala, with limited evidence regarding its impact; vaccine is currently absent from the national immunization program. Generating local data on the economic and health burden can support immunization policies. This study describes the use of hospital resources, costs of care, clinical and demographic characteristics, and complications in children with varicella.
View Article and Find Full Text PDFVaccines (Basel)
January 2025
Vaccine Center, School of Basic Medicine and Clinical Pharmacy, China Pharmaceutical University, Nanjing 211198, China.
Background/objectives: Approved mRNA vaccines commonly use sequences modified with pseudouridine to enhance translation efficiency and mRNA stability. However, this modification can result in ribosomal frameshifts, reduced immunogenicity, and higher production costs. This study aimed to explore the potential of unmodified mRNA sequences for varicella-zoster virus (VZV) and evaluate whether codon optimization could overcome the limitations of pseudouridine modification.
View Article and Find Full Text PDFVaccines (Basel)
January 2025
Institute of Immunization and Prevention, Zhejiang Center for Disease Control and Prevention, Hangzhou 310051, China.
: China has a high incidence rate of varicella yet a low coverage rate of the varicella vaccine (VarV), with safety concerns being a leading cause of the lack of vaccination willingness. This study aimed to describe VarV-related adverse events following immunization (AEFIs) and analyze their characteristics in Zhejiang, China, 2020-2022. : VarV-related AEFIs in Zhejiang Province from 1 January 2020 to 31 December 2022 were collected through the Chinese National AEFI Information System (CNAEFIS) for a descriptive epidemiological analysis.
View Article and Find Full Text PDFVaccines (Basel)
December 2024
Guangzhou Center for Disease Control and Prevention, Guangzhou 510440, China.
Seropositivity study of Varicella in Healthy Populations in Guangzhou, China. Infection with varicella-zoster virus (VZV) leads to skin and mucous membranes blisters and the complications can be life threatening. A seroepidemiological study conducted from 2020 to 2022 in Guangzhou, China, aimed to evaluate varicella antibody levels.
View Article and Find Full Text PDFEnter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!